NCT02949947View on ClinicalTrials.gov

Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 18, 2017

Primary Completion Date

March 6, 2019

Study Completion Date

March 6, 2019

Conditions
Malignant Neoplasms of Mesothelial and Soft TissueGastrointestinal Stromal Tumor With Neurogenic Differentiation
Interventions
DRUG

Ferric Carboxymaltose

15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.

DIETARY_SUPPLEMENT

Iron Supplements

Participants take iron supplements by mouth every day for up to 3 months.

BEHAVIORAL

Questionnaire

Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

American Regent, Inc.
All Listed Sponsors
collaborator

American Regent, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER